Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Pulike Biological Engineering's EV-to-FCF or its related term are showing as below:
SHSE:603566'
s EV-to-FCF Range Over the Past 10 Years
Min: -315.82 Med: 46.57 Max: 2090
Current: 14.84
During the past 13 years, the highest EV-to-FCF of Pulike Biological Engineering was 2090.00. The lowest was -315.82. And the median was 46.57.
SHSE:603566's EV-to-FCF is ranked worse than 50.72% of 345
companies
in the Biotechnology industry
Industry Median: 14.39
vs SHSE:603566: 14.84
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pulike Biological Engineering's PE Ratio (TTM) for today is calculated as:
Pulike Biological Engineering's share price for today is ¥10.39.
Pulike Biological Engineering's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pulike Biological Engineering EV-to-FCF Related Terms
Pulike Biological Engineering EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603566 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Pulike Biological Engineering's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulike Biological Engineering EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pulike Biological Engineering's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pulike Biological Engineering's EV-to-FCF falls into.
Pulike Biological Engineering's current Enterprise Value is ¥2,994 Mil.
Pulike Biological Engineering's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥200 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulike Biological Engineering (SHSE:603566) has a EV-to-FCF of 14.95 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pulike Biological Engineering and its competitors. This is 68% below median its historical median of 46.57. According to the industry distribution chart, Pulike Biological Engineering ranks #175 out of 345 companies in the Biotechnology industry, placing it in the top 50.7%.
Is Pulike Biological Engineering's EV-to-FCF too high?
Pulike Biological Engineering's current EV-to-FCF of 14.95 is 68% below median its 10-year median of 46.57. The Biotechnology industry median EV-to-FCF is 14.39. Pulike Biological Engineering's value of 14.95 is 3.9% above this industry median. Based on the distribution chart, Pulike Biological Engineering ranks #175 out of 345 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pulike Biological Engineering has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pulike Biological Engineering's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pulike Biological Engineering ranks #175 out of 345 companies for EV-to-FCF. This places Pulike Biological Engineering in the lower half of its industry. The industry median EV-to-FCF is 14.39. Pulike Biological Engineering's value of 14.95 is 3.9% above this benchmark. While the company's 10-year median is 46.57 vs. the industry median of 14.39, Pulike Biological Engineering has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.39, based on 345 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulike Biological Engineering's current EV-to-FCF of 14.95 is 3.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pulike Biological Engineering and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulike Biological Engineering's current EV-to-FCF is 14.95, which is 68% below median its own 10-year median of 46.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulike Biological Engineering stock overvalued right now?
Based on GuruFocus' analysis, Pulike Biological Engineering (SHSE:603566) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.39, compared to a current price of ¥10.39 — trading 27.8% below its estimated fair value. The current EV-to-FCF is 14.95, which is 68% below median its 10-year median of 46.57 and 3.9% above the Biotechnology industry median of 14.39. Pulike Biological Engineering's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pulike Biological Engineering (SHSE:603566), the current EV-to-FCF is 14.95 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulike Biological Engineering (SHSE:603566) Overvalued in 2026?
Based on GuruFocus' analysis, Pulike Biological Engineering stock appears to be undervalued.
The current stock price of ¥10.39 is trading 27.8% below its estimated GF Value™ of ¥14.39.
GuruFocus considers Pulike Biological Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:603566:
EV-to-FCF: 14.95 (68% below median its 10-year median of 46.57)
GF Value™: ¥14.39 vs. price of ¥10.39 (27.8% below fair value)
Industry Position: 3.9% above the Biotechnology median (#175 of 345)
No single metric tells the full story. See the SHSE:603566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603566 has been successfully added to your 
